{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056297","form_type":"8-K","ticker":null,"cik":"0001673772","company_name":"RAPT Therapeutics, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.521499+00:00","generated_at":"2026-06-02T06:21:09.419167+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"RAPT closes Phase 2b/2a trials after FDA hold due to liver failure SAE; Q1 net loss $30.5M","bullets":["Company to close and unblind Phase 2b atopic dermatitis and Phase 2a asthma trials of zelnecirnon following FDA clinical hold.","Clinical hold triggered by one patient liver failure requiring transplant; 229 patients enrolled in AD trial.","Net loss of $30.5M for Q1 2024 vs $29.3M in Q1 2023; cash and equivalents $141.6M.","Data analysis from AD trial expected Q3 2024 to inform development path and FDA discussions."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056297","json":"https://secwatch.observer/filing/0000950170-24-056297.json","markdown":"https://secwatch.observer/filing/0000950170-24-056297.md","text":"https://secwatch.observer/filing/0000950170-24-056297.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1673772/000095017024056297/0000950170-24-056297-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1673772/000095017024056297/rapt-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:21:09.419167+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3970625e871cfc6e6088095cee1a5cdf231eba42","claim":"RAPT Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income Net loss for the first quarter of 2024 was $30.5 million.","evidence_excerpt":"RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1673772/000095017024056297/0000950170-24-056297-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss for the first quarter of 2024 was $30.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}